Last week, Amgen and Allergan announced that the FDA will review data supporting the firms' Biologics License Application for ABP 215, a bevacizumab (Avastin) biosimilar candidate.
Last week, Amgen and Allergan announced that the FDA will review data supporting the firms’ Biologics License Application for ABP 215, a bevacizumab (Avastin) biosimilar candidate.
The FDA Advisory Committee will review the analytical, pharmacokinetic, and clinical data from studies on ABP 215, including the results of a phase 3 study that met its primary endpoint of demonstrating clinical equivalence to the reference product in patients undergoing treatment for non-squamous, non-small cell lung cancer. The study also demonstrated comparable safety and immunogenicity profiles for ABP 215 and the reference bevacizumab.
While Amgen and Allergan have said that they believe their product to be the first bevacizumab biosimilar submitted for consideration in the United States, the reference product’s manufacturer, Roche, sees competition brewing in Europe—the European Medicines Agency has confirmed that it is currently considering 2 applications for bevacizumab biosimilars.
Roche, in attempting to retain its hold on the $6.8 billion bevacizumab market, has asserted that its patent protection for bevacizumab extends until 2019. The firm filed a complaint in the US courts in response to Amgen and Allergan’s application, and seeks to bar the biosimilar product from the US market until the patent dispute has been resolved.
Roche’s argument hinges upon the so-called “patent dance” requirements as laid out in the Biologics Price Competition and Innovation Act. However, after this week’s Supreme Court ruling in Sandoz v Amgen, which held that the “patent dance” is optional, Roche may be forced to change its litigation approach.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.